Welcome to our dedicated page for Sanuwave Health SEC filings (Ticker: SNWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sanuwave Health, Inc. (SNWV) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K, proxy statements, and other regulatory documents. Sanuwave is a Nevada corporation whose common stock trades on NASDAQ under the symbol SNWV, and its filings offer detailed information on operations, governance, and financing.
Recent Forms 8-K describe results of operations and financial condition for specific quarters, including press releases announcing revenue, gross margin, operating income, and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Other 8-K filings cover material definitive agreements, such as a secured credit facility with JPMorgan Chase Bank, N.A. that includes a term loan and revolving credit facility, and the termination of a prior debt facility with NH Expansion Credit Fund Holdings LP.
Additional 8-K items document corporate actions and governance events, including changes in executive officers, separation and release agreements, stockholder meeting results, and amendments to the 2024 Equity Incentive Plan. One filing also describes a license and option agreement related to intravascular shockwave patents and the subsequent exercise of the option by the licensee, resulting in a cash payment to Sanuwave.
Investors interested in capital structure and shareholder matters can review the company’s definitive proxy statement (DEF 14A), which discusses director elections, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and details of the reverse stock split of Sanuwave’s common stock.
On Stock Titan, these filings are updated from the SEC’s EDGAR system, and AI-powered tools can help summarize key points, highlight significant items in Forms 8-K, and clarify the implications of proxy proposals and financing agreements. This allows readers to quickly understand how Sanuwave’s regulatory disclosures relate to its advanced wound care and regenerative medicine business.
Solas Capital Management, LLC and Frederick Tucker Golden report beneficial ownership of 296,691 shares of SANUWAVE Health, Inc. common stock, representing 3.5% of the outstanding shares based on 8,555,616 shares outstanding as of May 5, 2025. The filing clarifies that Solas acts as an investment adviser to private funds and Mr. Golden, as portfolio manager, shares voting and dispositive power over these shares.
The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. Both Solas and Mr. Golden report no sole voting or dispositive power and shared voting and dispositive power over all 296,691 shares.
SANUWAVE Health, Inc. (SNWV) filed an Form 8-K dated 8-Aug-2025 under Item 2.02 to furnish—not file—a press release announcing its financial results for the quarter ended 30-Jun-2025. The detailed numbers are contained in Exhibit 99.1, which is not reproduced in the body of this report. Management will host a business-update conference call on 8-Aug-2025 at 8:30 a.m. EST; supporting materials are available on the investor section of the company’s website. The filing also lists Exhibit 104, which embeds the cover-page XBRL tags, and confirms that the information is excluded from Section 18 liability and is not incorporated by reference into other Securities Act filings.